Clinical and Biological Principles of Cold Atmospheric Plasma Application in Skin Cancer

Jesús Gay-Mimbrera · Maria Carmen García · Beatriz Isla-Tejera · Antonio Rodero-Serrano · Antonio Vélez García-Nieto · Juan Ruano

Received: March 21, 2016 / Published online: May 3, 2016 © The Author(s) 2016. This article is published with open access at Springerlink.com

ABSTRACT

Plasma-based electrosurgical devices have long been employed for tissue coagulation, cutting, desiccation, and cauterizing. Despite their clinical benefits, these technologies involve tissue heating and their effects are primarily heat-mediated. Recently, there have been significant developments in cold atmospheric pressure plasma (CAP) science and engineering. New sources of CAP with well-controlled temperatures below 40 °C have been designed, permitting safe plasma application on animal and human bodies. In the last decade, a new innovative field, often referred to as plasma medicine, which combines plasma physics, life science, and clinical medicine has emerged. This field aims to exploit effects of mild plasma by controlling the interactions between plasma components (and other secondary species that can be formed from these components) with specific structural elements and functionalities of living cells. Recent studies showed that CAP can exert beneficial effects when applied selectively in certain pathologies with minimal toxicity to normal tissues. The rapid increase in new investigations and development of various devices for CAP application suggest early adoption of cold plasma as a new tool in the biomedical field. This review explores the latest major achievements in the field, focusing on the biological effects, mechanisms of action, and clinical evidence of CAP applications in areas such as skin disinfection, tissue regeneration, chronic wounds, and cancer.

Enhanced content To view enhanced content for this article go to www.medengine.com/Redeem/E2C4F06001B9A0F0.

J. Gay-Mimbrera · B. Isla-Tejera · A. V. García-Nieto · J. Ruano (✉)
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofia, University of Córdoba, Córdoba, Spain
E-mail: juanruanoruzi@mac.com

M. C. García
Department of Applied Physics, University of Córdoba, Córdoba, Spain

B. Isla-Tejera
Department of Pharmacy, Hospital Universitario Reina Sofía, Córdoba, Spain

A. Rodero-Serrano
Department of Physics, School of Engineering Science of Belmez, University of Córdoba, Córdoba, Spain

A. V. García-Nieto · J. Ruano
Department of Dermatology, Hospital Universitario Reina Sofía, Córdoba, Spain
treatment. This information may serve as a foundation for the design of future clinical trials to assess the efficacy and safety of CAP as an adjuvant therapy for skin cancer.

**Keywords:** Apoptosis; Cold atmospheric plasma; Dermatology; Keratinocytes; Melanoma; Non-melanoma skin cancer; Oncology

**CHARACTERISTICS OF COLD ATMOSPHERIC PLASMA**

Plasma is an ionized gas that is composed of ions, electrons, photons, and neutrals (radicals as well as excited atoms and molecules). All are active species capable of inducing different physical phenomena and chemical reactions. There are many examples of plasma in nature, such as plasmas that are generated in stars and the polar aurora. Plasmas can also be created in the laboratory setting; here, plasmas are maintained by applying an external source of energy, generally an electromagnetic field, to a gas. Plasma technology has gained much interest in recent years owing to its various applications in fields such as microelectronics, waste elimination, lighting, and textile. Several nonthermal plasma sources have been recently developed. These plasma sources can be well controlled and open to the air, allowing for the maintenance of CAPs with temperatures below 40 °C. These developments have encouraged therapeutic application of CAPs and the emergence of plasma medicine technology.

Nonetheless, plasma application on the human body for medical purposes has a significant history. In the mid-nineteenth century, electrotherapy was introduced as a therapeutic approach, and spark and flash discharges were employed to treat several diseases. Later, electrosurgical techniques based on the use of plasmas were developed. In electrosurgery, selective coagulation or tissue cutting is achieved by tissue heating which results in desiccation of cells, denaturation of proteins, or devitalization of tissues [1]. Argon plasma coagulation (APC) is a well-established method in the field and commonly employed today for tissue coagulation during endoscopy (in gastroenterology, general and visceral surgery, urology, or gynecology) [2]. APC is a monopolar technique introduced in the 1970s, in which electrical energy is transferred to target tissue as current by means of argon plasma. This technique competes with traditional laser ablation. Comparative studies have shown that APC is more effective for tissue destruction owing to its superior energy concentration. Furthermore, PlasmaJet®, another electrosurgical technique, possesses activity that is mostly mediated by thermal (thus destructive) interaction with living tissues. It consists of a bipolar electrode system with low-flow argon as the process gas. This technique is typically employed to cut or coagulate tissues in a well-defined and localized manner. These direct plasma applications on living tissues in electrosurgery are based on extreme interactions of plasma with cells or tissue, which may lead to cellular destruction and local “sealing” of tissue.

In the last decade, with the development of CAPs, modern plasma medicine has emerged. This branch of medicine aims to exploit the effects of mild plasma by utilizing the distinct interaction of plasma components (and other secondary species than can be formed from these) with specific structural elements as well as functionalities of living cells [1]. These interactions may lead to either stimulation or inhibition of cellular function; thus, this technique may be employed for various
therapeutic purposes [3]. While most clinical studies have been conducted in the area of dermatology, interests in CAP technology have also emerged from other disciplines, such as oncology, surgery, otolaryngology, gastroenterology, and odontology [4, 5].

Sources of Cold Atmospheric Plasma

New CAP sources used in plasma medicine can be classified into three types [6]:

1. **Direct plasma sources** These plasmas use the human body (such as the skin, internal tissues, etc.) as an electrode; thus, the current produced by plasmas has to pass through the body. The most utilized technology in this category is the dielectric barrier discharge (DBD) plasma source.

2. **Indirect plasma sources** These plasmas are generated between two electrodes. Active species that are created by the plasmas are subsequently transported to target application areas. Several devices are available, ranging from very narrow plasma needles or jets to larger plasma torches such as the kINPen® MED, Atmospheric Pressure MicroPlasma Jet (APMPJ), and MicroPlaSter® α and β.

3. **Hybrid plasma sources** These plasmas combine the benefits of the two aforementioned plasma source types (e.g., using the plasma production technique of direct plasma sources and the essentially current-free property of indirect plasma sources). This is achieved by introducing a grounded wire mesh electrode, which has a significantly smaller electrical resistance than that of the tissue; thus, in principle, all current can pass through the wire mesh. The MiniFlatPlaSter is an example of a hybrid plasma source.

Nevertheless, plasmas can also be generated by discharges in air, noble gases, or any desired mixture. They can be excited by various means, including radio frequency, microwave frequencies, and high voltage AC or DC, in continuous or pulsed mode in order to produce a chemical cocktail of active species for biomedical applications. Table 1 summarizes the properties of various types of plasma reactors that have been employed for dermatological purposes. In cold atmospheric pressure plasma sources, the main reactive components are reactive neutral species (including free radicals and few ground state molecules such as peroxides and ozone) and UV radiation. Because CAP sources operate at atmospheric pressure while in contact with air, they generate copious quantities of reactive oxygen species (ROS) and reactive nitrogen species (RNS), collectively referred to as RONS. A list of RONS was provided in a recent review, which also highlighted the role of these species in redox biology and their implications for therapeutic applications of plasma [7]. RONS can strongly influence cellular biochemistry and are known to be important in animal and plant immune systems, supporting the notion that they are indeed key mediators in CAP therapeutics.

Here, we review the latest evidence of the biological effects, mechanisms of action, and clinical benefits of CAP application in dermatology. This review also highlights the potential application of CAP as co-adjuvant therapy for the treatment of skin tumor. Analyses described in this review article were based on previously conducted studies. No studies involving human subjects or animals were performed for the publication of this review.
### Table 1 Summary of plasma sources used in dermatology

| Type of plasma source | Plasma source | Device | Gas | Frequency | Flow | Power/discharge voltage | Treatment |
|-----------------------|---------------|--------|-----|-----------|------|--------------------------|-----------|
| Direct plasma source  | DBD PlasmaDerm®, CINOXY GmbH | Ar DC | 8 slm | 0.17–0.24 W/14 kV | Melanoma [36] |
|                       |               | Pulsed 100–400 Hz |           |           | Chronic ulcer [42]       |           |
|                       |               | Pulsed 60 Hz | | | Skin moisture [47]       |           |
| Custom design         | Ar + O₂ DC   | No flow | 0.9 W/20 kV | Keratinocytes effect [15] |
| Custom design         | Air DC       | No flow | 0.2–0.4 W/5–6 kV | Wound healing [49] |
| Custom design (point to plane arrangement) | Air 100 kHz Pulsed 300 Hz | No flow | 14 kV | Skin treatment (physical model) [50] |
| DBD, INP Greifswald  | Air 31 kHz | No flow | 0.4–1.6 W/13 kV | Study of skin irritation [51] |
| DBD plasma strip      | Air 6.6 kHz | No flow | 0.7 W/3.5 kV | Infected wound [52] |
| Direct DBD-Bioplasma cell modulation | Air 15–20 kHz Pulsed 10–110 Hz | No flow | 40 W/6–7 kV | Acne and aesthetic treatment [53] |
| Surface DBD           | Air/Ar 20–21 kHz No flow/0.5 slm | 0.14–0.3 W/3.5–10 kV | Wound healing [54] |
| Volumen DBD           | Ar 33 kHz | 0.5 slm | 6 W/9–10 kV | Wound healing [54] |
| Indirect plasma source | Jets kINPen® MED, neoplas tools GmbH | Ar 1–1.5 MHz | 3–8 slm | 1–6 kV | Skin decontamination [55] |
|                       |               | Pulsed |           |           | Psoriasis [43]           |           |
|                       |               |           |           |           | Melanoma [50]            |           |
|                       |               |           |           |           | Skin moisture [31]       |           |
|                       |               |           |           |           | Plasma effect in stratum corneum [56] |           |
|                       |               |           |           |           | Wound healing [4, 18, 57, 58] |           |
| Type of plasma source | Plasma source | Device | Gas          | Frequency | Flow | Power/discharge voltage | Treatment                                           |
|----------------------|--------------|--------|--------------|-----------|------|-------------------------|-----------------------------------------------------|
| Custom design        | Ar/He        | 10 kHz | 2 slm        | 8/10 kV   |      | Human mesenchymal stromal cells [30] |
| Custom design        | He           | 230–270 kHz | 2 slm | 1.1–1.8 kV |      | Melanoma [35, 57]        |
| APMPJ                | He           | 60 kHz | 1 slm        | 5–5.5 kV  |      | Endoscopic sterilization [4] |
| Custom design        | He           | RF 25 kHz | 16.5 slm | 25 kV    |      | Wounds healing [58]      |
| HF plasma jet        | Ar           | 1.82 MHz Continuous/pulsed 10 kHz | 2 slm     | 2–3 W/0.4–0.6 W |      | Study of plasma irritation [51] |
| RF APPJ              | Ar           | 13.56 MHz | 1.5 slm     | 1.7 W    |      | Antibacterial [59]       |
| Torches              | MicroPlaSter®, terraplasma GmbH | 2.45 GHz | 2.2–4 slm   | 86–110 W |      | Infected wound [51]      |
|                      |              |        |              |           |      | Wound healing [9, 24, 40, 41] |
|                      |              |        |              |           |      | Keratinocytes effect [19] |
|                      |              |        |              |           |      | Pruritus [45]             |
| Hybrid plasma source | SMD technology | Custom design | Air | 12.5 kHz | No flow | 0.5 W m\(^{-2}\)/18 kV | Nosocomial infections [60] |
|                      |              | MiniFlatPlaSter | Air | Pulsed 6.75 kHz | No flow | 7 kV | In vivo skin disinfection (bacteria) [61] |
|                      |              |        |              |           |      | Ex vivo nasal and pharyngeal mucosa [48] |
|                      |              |        |              |           |      | Melanoma [13]             |
BIOLOGICAL EFFECTS AND MECHANISMS OF ACTION OF COLD ATMOSPHERIC PLASMA

CAP is a gas composed of multiple chemically active species. It induces physical and chemical changes on biological surfaces upon application. In recent years, several studies have demonstrated biological effects of these changes. Elucidation of the key mechanism behind the effects of CAP in cancerous cells will be crucial to determine the optimal dose of CAP for clinical use.

Oxidative Stress

The level of intracellular ROS and RNS (RONS) is tightly regulated by small antioxidant molecules and scavenging enzymes. At low concentrations, RONS are involved in various biological processes such as bacterial destruction by macrophages and endothelial nitric oxide-mediated vasodilatation. However, when their levels exceed the capacity of the redox balance control system, a state referred to as oxidative stress, they can be cytotoxic and cause cell death. Oxidative stress is involved in the development of various diseases such as psoriasis, chronic ulcers, and cancer.

Cancer cells display weaker antioxidant mechanisms when compared to normal cells. This property can facilitate selective attack of cancer cells by CAP mediated by the extracellular RONS, resulting in severe oxidative damage and cell death. Schmidt et al. observed that alterations in redox state due to CAP treatment caused changes in cellular morphology and mobility, but not cell viability [8]. The authors also found that oxidative stress induced by CAP can modify the expression of nearly 3000 genes encoding structural proteins and inflammatory mediators, such as growth factors and cytokines.

Gene Expression and Epigenetic Changes

Numerous studies have assessed the effects of CAP on gene expression and epigenetics in several cell lines. Application of CAP for 2 min with the MicroPlaSter β® device on a fibroblast culture and in a wound healing mouse model increased the expression of type I collagen and genes encoding proteins involved in wound healing processes (interleukin 6 [IL-6], IL-8, chemokine [C–C motif] ligand 2 [CCL2], transforming growth factor beta 1 [TGF-β1], TGF-β2, CD40 ligand, chemokine [C–X–C motif] ligand 1 [CXCL1], interleukin 1 receptor antagonist [IL-1RA], and plasminogen activator inhibitor-1 [PAI-1]) without affecting cellular migration, proliferation, and apoptosis [9]. Zhong et al. demonstrated the downregulation of IL-12 and upregulation of IL-1β, IL-6, IL-8, IL-10, tumor necrosis factor α (TNFα), interferon gamma (IFNγ), and vascular endothelial growth factor (VEGF) mRNAs when CAP was applied to keratinocyte cultures [10]. Park et al. demonstrated for the first time changes in DNA methylation pattern following CAP application in a breast cancer cell line expressing the estrogen receptor (MCF-7) and one that does not express it (MDA-MB-231). Epigenetic modifications were more extensive in MCF-7 cells, affecting the promoter region of genes related to “cell mobility”, “connective tissue function and development”, “motility development”, “cell–cell communication and cell–cell interaction”, and “cell survival and cell death” [11].
Mitochondria, Cell Cycle, and Apoptosis

Apoptosis is a type of programmed cell death, and mitochondria act as the major regulator of apoptosis. Various intracellular and extracellular signals induced by CAP-mediated oxidative stress converge in mitochondria, increasing their transmembrane potential and promoting the release of pro-apoptotic factors including cytochrome c. This process is regulated by the Bcl-2 protein family and ultimately leads to the activation of the caspase cascade [12]. Arndt et al. showed that when CAP was applied for 2 min to a melanoma cell line, pro-apoptotic changes such as Rad17 and tumor suppressor p53 phosphorylations, cytochrome c release, and caspase-3 activation were initiated [13].

The cell cycle is a series of events leading to cell replacement in tissues. RONS produced following high dose application of CAP can alter the cell cycle, which typically leads to apoptosis. However, lower doses of CAP can also inhibit cell proliferation by inducing cell senescence, especially when most cells in the tissue are in the proliferative phase, as observed in most tumors [13]. Typically, normal tissues differ from tumor in the proportion of cells in each cell cycle phase at a given time. In fact, this could be the biological mechanism behind the high selectivity of CAP to induce apoptosis of these cells while preserving viability of non-tumor cells. Yan et al. demonstrated that CAP increased the percentage of apoptotic tumor cells by blocking the cell cycle at the G2/M checkpoint, and this effect was mediated by reduced intracellular cyclin B1 and cyclin-dependent kinase 1 (Cdc2), increased p53 and cyclin-dependent kinase inhibitor 1 (p21), and increased Bcl-2-like protein 4 (Bax)/B cell lymphoma 2 (Bcl-2) ratio [14]. However, it is important to mention that the viability of non-tumor cells can also be altered if cells are exposed to CAP for a longer period of time [15].

EFFECTS OF COLD ATMOSPHERIC PLASMA ON NORMAL SKIN CELLS

In a laboratory setting, several studies have been performed to determine the effect of CAP applied to cells that are part of the epidermal (i.e., keratinocytes and melanocytes) or dermal (fibroblasts) cytoarchitecture. In these studies, dose-dependent effects of CAP on cells were observed. CAP application for less than 2 min on keratinocytes and fibroblasts was not associated with increased cell toxicity or apoptosis. However, lower or higher doses may stimulate or inhibit cell migration (fibroblasts) and proliferation (fibroblasts and keratinocytes), respectively. Most of these studies utilized normal melanocytes as a control for melanoma cells. The latest evidence of the effects of CAP on skin cells is summarized in this review.

The antiproliferative effects of CAP have been associated with increased numbers of keratinocytes in the G2/M phase [16]. Wende et al. evaluated 40-s CAP application on an in vitro model of wound healing based on culture of human keratinocytes colonized by Staphylococcus epidermidis [17]. Bacterial load reduction and closure of artificial wound were improved following CAP application when compared to the control. Hasse et al. investigated the ex vivo effects of CAP applied to healthy human skin samples for a longer period of time. In this study, while epidermis integrity and expression pattern of various keratins remained unchanged, basal proliferation of keratinocytes was found to be increased after 1–3 min of CAP exposure. Apoptosis was induced only when CAP was applied for 3–5 min [18]. This proliferative effect achieved using short exposure time may be
beneficial to expedite healing processes. Other studies have demonstrated increased expression of IL-8, TGB-1β/TGB-β2, and β-defensin mRNA 24–48 h following keratinocytes exposure to CAP for 2 min, with no observable modification of cell proliferation, migration, or apoptosis [19].

Wound healing is a complex and dynamic biological process that requires the sequential coordination of cells, cytokines, chemokines, and proteins of the renin–angiotensin system. The time when resident fibroblasts achieve the capacity to produce growth factors and generate a collagen network is a critical point in the tissue restoration process [20]. Shashurin et al. observed that fibroblast adhesion and migration were halved following 5-min CAP application, which appeared concurrently with the downregulation of α and β integrins (10% and 22%, respectively) [21]. A subsequent study, in which CAP was applied on a human skin-derived fibroblast culture for less than 1 min, showed absence of cell proliferation and apoptosis changes [22]. However, opposing effects were observed in other studies. Tipa and Kroesen applied CAP on a cell culture-based wound model for 5–15 s and found that fibroblasts were able to cover the artificial wound more rapidly without any observable cytotoxic effects [23]. The observed increase in the proliferative and migration capacities of fibroblasts may be linked to peroxisome proliferator-activated receptor gamma (PPARγ) activation mediated by elevated intracellular ROS [19].

STANDARDIZATION OF PROCEDURES AND SAFETY ASSESSMENT

Several factors can influence the interpretation of the effects of CAP on cells and tissues, making it challenging to compare results obtained by different researchers. A standardized system of procedures related to plasma sources, devices, and treatment doses used in each study is necessary. Currently, only the DIN General Requirements of Plasma Sources in Medicine (DIN SPEC 91315, 2014), which was presented at the 5th International Conference on Plasma Medicine (ICPM5), has been published.

While most studies conducted in human subjects have described the short-term safety profile of the plasma device, there is currently no consensus on which strategy should be used to address this issue. In several studies, a tissue tolerable plasma (TTP) was determined. For example, Isbary et al. evaluated the tolerability and safety of CAP applied using the FlatPlaSter 2.0 and MiniFlatPlaSter devices through histology, electron microscopy, and DNA damage evaluations [24]. Ma et al. determined that the intracellular mechanisms were the most effective in protecting cells from oxidative stress induced by plasma by reducing cell death [25]. Lademann et al. focused on assessing the effects of UV radiation and temperature on the skin following CAP applications in several patients and healthy volunteers. They showed that UV radiation emitted by CAP was an order of magnitude lower than the minimal erythematic dose (the minimum dose needed to produce sunburn in the skin in vivo) and no thermal damage was observed in the CAP-treated areas [26]. Wende et al. recently used standardized procedures to evaluate the mutagenic potential of kINPen® MED plasma in the clinic [27]. They demonstrated that RONS generated by the plasma were not able to interact directly with DNA or were found in low concentrations, which should allow for DNA damage repair by cellular mechanisms. Thus, plasma was determined to be non-genotoxic to human
cells in vitro. Lastly, it should be highlighted that despite these attempts, in vivo studies evaluating potential long-term side effects of CAP have yet to be conducted.

ANTITUMOR EFFECTS OF CAPS AND THEIR POTENTIAL APPLICATION IN DERMATOLOGY

CAP has shown a significant anticancer capacity over a wide range of cancer types. Several studies have found that tumor cells are more sensitive to CAP compared to normal cells; thus, this technology should be considered for an ideal cancer treatment.

As described previously, CAP can selectively induce apoptosis of tumor cells [28]. This feature supports CAP as a new therapeutic tool that complements the clinical benefits obtained with conventional treatments, as the latter may result in the damage of surrounding healthy tissues and are associated with greater treatment costs and/or risk of adverse effects. In contrast to chemotherapy and radiotherapy, the most attractive feature of CAP is its selective capacity for killing cancer cells. To date, several studies have demonstrated the benefit of CAP jet application on culture of cells obtained from human tumors or in immortal cell lines and animal models (Table 2). The selectivity of CAP was not only observed in cancer cells but also in various cancer cell lines. The killing capacity of CAP is dose-dependent and inversely proportional to the growth speed of cancer cells. Different studies have examined the effects of CAP on cell adhesion, migration, and invasive capacities. CAP can decrease cell adhesion without causing necrosis. In fact, CAP was able to induce detachment of certain cells through the action of ROS on the outer cell membrane without necessarily causing any intracellular changes [29]. This effect appeared to be reversible; thus, it can serve as the basis of future CAP applications in tumor microsurgery.

Data related to the percentage or timing of the improvement achieved after CAP treatment vary widely among studies. There are many methodological differences (type of CAP, exposure time, and distance to cells) that make it difficult to compare the results (i.e., cell apoptosis after CAP application varies from 20% to 40% of melanoma cells and <10% of melanocytes) [13]. Related to the time needed to achieve the improvement, most of the reviewed studies were performed after applying CAP for 1–180 s on cell cultures (Table 2). Short-time effects were assessed after 1–3 days in most of the cases; longer periods are needed to explore chronic effects, but in that case is not possible to use cell cultures because of confluency of cells; thus, animal models should be used for that purpose.

In most studies, CAP was applied directly to cells or tissues. However, over the past 4 years, CAP-irradiated media have also been found to effectively kill cancer cells. These media were used on mesenchymal stroma and LP-1 myeloma cell lines, and the majority of the observed effects were mediated by H$_2$O$_2$ and O$_2$ species [30]. Yan et al. recently determined H$_2$O$_2$ as the main reactive species and cysteine as the central target molecule of CAP-irradiated media used on glioblastoma and breast cancer cells [31]. Plasma-activated water (PAW), an example of a CAP-irradiated media, is a promising anticancer therapeutic that has several advantages over the direct CAP application. These advantages should be accounted for if PAW implementation in the clinic is considered. PAW can be stored in a refrigerator for 1 week without losing its anticancer properties [32]. This feature will
### Table 2  Biological effects of cold plasma in preclinical models of various cancers

| Non-skin tumors                  | Plasma                   | Exposure time               | Model                                      | Explored features                                      |
|----------------------------------|--------------------------|----------------------------|--------------------------------------------|--------------------------------------------------------|
| Lymphoma [62]                   | DBD plasma               | Various, from 30 to 480 s   | Human mononucytic lymphoma cell line (U937) | Metabolic activity, cell viability, and apoptosis      |
| Breast cancer [63]              | Custom design            | 30, 60, and 120 s          | Human metastatic cell line (MDA-MB-231)    | Cell proliferation and migration                       |
| Ovarian cancer [64]             | NEAPP                    | Various, from 2 to 600 s    | Ovarian cancer cell lines (SKOV3 and HRA)  | Cell proliferation and apoptosis                       |
| Colorectal cancer [65]          | Torch with spray         | 1 s                        | Colorectal cancer cell lines               | Migration and invasion                                 |
| Lung cancer [66]                | Plasma plume             | 10 s                       | Human lung adenocarcinoma cell line (A549) | DNA damage and cell viability                         |
| Liver cancer [67]               | Microsize jet-type plasma| 2 min                      | Human liver cancer cell line (SK-HEP-1)    | Cell adhesion                                         |
| Lung carcinoma [68]             | Custom design (CU)       | 20 s                       | TC-1 mouse lung carcinoma cells            | Apoptosis                                              |
| Pancreatic cancer [69]          | Plasma jet kINPen 09     | 5, 10, and 20 s             | Human pancreatic cancer cell line (Colo-357 and PaTu8988T)/murine cell line (6606PDA) | Cell viability and apoptosis                           |
| Non-cutaneous squamous cell carcinoma [70] | Custom design (GWU) | 10, 30, and 45 s | Head and neck squamous cell carcinoma cell lines | Cell viability and colony formation                    |
| Prostate cancer [71]            | Custom design            | –                          | Human and cell lines                      | Cell viability, gene expression, and apoptosis         |
| Prostate cancer [72]            | μ-APPJ                   | Various, from 2 min to 20 min| PC-3 prostate cancer cells                | Cell viability, protein expression, and nitric oxide quantitation |
| Prostate cancer [73]            | kIN-Pen Med              | 10 s                       | Human epithelial PC cell lines (LNCaP and PC-3) | Cell proliferation and apoptosis                       |
| Glioma [74]                     | DBD plasma               | –                          | Human glioma cell line (U373MG)            | Cell viability                                         |
| Glioblastoma [75]               | DBD plasma               | 20 s/day × 3 days          | U87-Luc glioma tumor on athymic BALB/c nude and C57bl6 mice | Temperature and antitumor effects                      |
| Glioblastoma [76]               | SMD plasma               | 30, 60, and 120 s          | Human glioblastoma cancer cell lines       | Cell viability, DNA damage, and cell cycle             |
permit the central production of PAW in hospitals using a single plasma generator. PAW can then be packaged and distributed to various operating rooms as needed for cancer treatments within the same day. Moreover, PAW can be applied topically on tumor surfaces or injected into the tumor [33]. This feature is significant in dermatology because skin tumors are easily accessible using these approaches. However, basic principles to guide PAW application in cancer, specifically to treat skin cancer, remain undefined.

Oxidative stress may play various roles in the pathogenesis of human skin cancers. The most clinically relevant dermatological tumors are the basal cell carcinoma, cutaneous squamous cell carcinoma, and malignant melanoma. Melanoma cells exhibit increased oxidative stress, which could damage surrounding tissue, thereby supporting the progression of metastasis [34]. When CAP was applied on an immortal melanoma cell line for 2 min, apoptosis was induced in cancer cells, but not in non-neoplastic melanocytes [13]. CAP treatment for 1 min did not induce apoptosis, although a prolonged inhibition of cell proliferation was observed, promoting cell senescence. Importantly, this demonstrated the ability of CAP application to remove tumor cells from the proliferative phase of the cell cycle. Ishaq et al. also observed a similar effect by comparing a line of melanoma cells to melanocytes in culture [35]. Elevated intracellular ROS induced the expression of genes involved in cellular apoptosis mediated by TNF-α and apoptosis signal-regulating kinase (ASK). When cells were pretreated with N-acetylcysteine and an antibody against TNF-α, the apoptosis signal was inhibited. Recently, Daeschlein et al. evaluated the antitumor efficacy of CAP administered in conjunction with a bleomycin-based electrochemotherapy in a mouse model of melanoma. The combinational therapy improved mice survival significantly when compared to the electrochemotherapy alone [36].

To date, experimental and/or clinical studies of CAP use in non-melanoma skin cancer (such as basal cell carcinoma and squamous cell carcinoma) have yet to be conducted. In non-melanoma skin cancer, diminished

| Non-skin tumors | Plasma | Exposure time | Model | Explored features |
|-----------------|--------|---------------|-------|-------------------|
| Glioblastoma [77, 78] | Custom design (GWU) | Various, from 60 to 180 s | Human glioblastoma cancer cell line (U87) | Cell viability, cell cycle, and apoptosis |
| Glioblastoma [79] | DBD plasma | 30, 60, 90, and 180 s | Glioma cell lines (U87, U373, A172), human normal astrocytes E6/E7, and HUVEC | Cell viability, cell cycle, and apoptosis |
| Neuroblastoma [80] | Helium-based plasma | 0, 30, 60, and 120 s | Neuro2a cells murine neuroblastoma | Metabolic activity and apoptosis |

HUVEC human umbilical vein endothelial cells, μ-APPJ micro-scaled atmospheric pressure plasma jet, GWU George Washington University, NEAPP non-equilibrium atmospheric pressure plasma, DBD dielectric barrier discharge, CU Clemson University, SMD surface micro discharge.
antioxidant defense caused by chronic UV exposure may contribute to carcinogenesis [34]. A related study, assessing the use of CAP in cultured explants of human low-degree non-cutaneous epidermoid carcinoma of the head and neck, demonstrated that plasma can decrease cell viability and increase DNA fragmentation and cell apoptosis [37].

CLINICAL USE OF CAP IN HUMAN SKIN

Few studies have addressed the effects of CAP in humans, and studies related to skin cancer have not been performed. Most clinical trials evaluated the efficacy and safety of cold plasma application, mainly as adjuvant treatment of chronic cutaneous ulcers. This is due to the frequent bacterial colonization or wound infection in chronic cutaneous ulcers that may affect adequate restitution of tissue structure and function. Furthermore, development of bacterial resistance is unlikely based on CAP mechanism of action [38, 39]. Study design and information obtained on CAP efficacy and safety can serve as a foundation to develop future clinical trials to assess CAP as a treatment option for skin cancer [40–42]. Virtually all clinical studies of CAP have been performed using medical devices designed for topical application (MicroPlaSter® α, MicroPlaSter® β, and PlasmaDerm® VU 2010), following a phase I or II clinical trial design using small numbers of healthy volunteers or patients (from 14 to 70). In all cases, treatment was well tolerated and no significant differences in adverse effect frequency were observed in the CAP group as compared to the controls. Results obtained from other studies on CAP application in human subjects are circumstantial; most were communicated as case reports or small series of cases, and all studies were performed in non-cancerous skin diseases. In most studies, CAP treatment was not more effective than the placebo; however, it was well tolerated with no relevant adverse events [43–45]. Recently, Metelmann et al. published a retrospective review of 12 patients with head and neck non-cutaneous advanced squamous cell carcinoma that were treated with CAP to decontaminate infected cancer ulcerations. When they evaluated anticancer effects, superficial partial remission of tumor was observed in some cases following CAP exposure [46].

CONCLUSION

The recent development of new plasma sources and devices for simple CAP application on the skin paralleled numerous studies performed in vitro, ex vivo, and in human subjects. When applied directly or indirectly on cell cultures or disease models (in vitro or in vivo using animal models), CAP has been shown to reduce cell proliferation, adhesion, and migration, and induce selective apoptosis of neoplastic cells without damaging normal cells. These selective effects may be due to differences in the intracellular oxidative status and cell cycle phase between normal and tumor tissues. Furthermore, excessive levels of oxidative radicals induced by CAP can induce DNA damage and cell cycle exit into senescence, apoptosis, or necrosis. The antitumor capacity of CAP treatment can been regulated by controlling treatment time, gas source composition, gas flow rate, and supply voltage. When CAP is utilized to irradiate a medium or water to obtain WAS, the distance between CAP source and the liquid, and the final volume should be taken into consideration. Despite mounting evidence supporting its use, studies
of CAP in human subjects are still limited. In the majority of these studies, CAP was shown to be well tolerated without any observable short-term adverse effects. Therefore, we suggest further investigation of CAP, including the use of PAW, as potential adjuvant therapies for skin tumors such as basal cell carcinoma, squamous cell carcinoma, and malignant melanoma.

**ACKNOWLEDGMENTS**

No funding or sponsorship was received for this study or publication of this article. All authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. The authors would like to thank Editage (http://www.editage.com) for English-language editing.

**Disclosures.** Jesús Gay-Mimbrera, María Carmen García, Beatriz Isla-Tejera, Antonio Rodero-Serrano, Antonio Vélez García-Nieto, and Juan Ruano have nothing to disclose.

**Compliance with Ethics Guidelines.** Analyses described in this review article were based on previously conducted studies. No studies involving human subjects or animals were performed for the publication of this review.

**Open Access.** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**REFERENCES**

1. von Woedtke Th, Reuter S, Masur K, Weltmann KD. Plasmas for medicine. Phys Rep. 2013;530:291–320.

2. Raiser J, Zenker M. M. Argon plasma coagulation for open surgical and endoscopic applications: state of the art. J Phys D Appl Phys. 2006;39:3520–3.

3. Heslin C, Boehm D, Milosavljevic V, Laycock M, Cullen PJ, Bourke P. Quantitative assessment of blood coagulation by cold atmospheric plasma. Plasma Med. 2014;4:153–63.

4. Zuo X, Wei Y, Wei Chen L, Dong Meng Y. Non-equilibrium atmospheric pressure microplasma jet: an approach to endoscopic therapies. Phys Plasmas. 2013;20:083507.

5. Kong MG, Kroesen G, Morfill G, et al. Plasma medicine: an introductory review. New J Phys. 2009;11:115012.

6. Isbary G, Zimmermann JL, Shimizu T, et al. Non-thermal plasma—more than five years of clinical experience. Clin Plasma Med. 2013;1:19–23.

7. Graves DB. The emerging role of reactive oxygen and nitrogen species in redox biology and some implications for plasma applications to medicine and biology. J Phys D Appl Phys. 2012;45:263001.

8. Schmidt A, von Woedtke T, Bekeschus S. Periodic exposure of keratinocytes to cold physical plasma—an in vitro model for redox-related diseases of the skin. Oxid Med Cell Longev. 2016;2016:9816072.

9. Arndt S, Unger P, Wacker E, et al. Cold atmospheric plasma (CAP) changes gene expression of key molecules of the wound healing machinery and improves wound healing in vitro and in vivo. PLoS one. 2013;8:e79325.

10. Zhong S, Dong Y, Liu D, et al. Surface air plasma induced cell death and cytokines release of human keratinocytes in the context of psoriasis. Br J Dermatol. 2016;174:542–52.

11. Park S-B, Kim B, Bae H, et al. Differential epigenetic effects of atmospheric cold plasma on MCF-7 and MDA-MB-231 breast cancer cells. PLoS One. 2015;10:e0129931.
12. Ahn HJ, Kim KI, Kim G, Moon E, Yang SS, Lee JS. Atmospheric-pressure plasma jet induces apoptosis involving mitochondria via generation of free radicals. PLoS One. 2011;6:e28154.

13. Arndt S, Wacker E, Li YF, et al. Cold atmospheric plasma, a new strategy to induce senescence in melanoma cells. Exp Dermatol. 2013;22:284–9.

14. Yan X, Zou F, Zhao S, et al. On the mechanism of plasma inducing cell apoptosis. IEEE Trans Plasma Sci. 2010;38:2451–7.

15. Kim KC, Piao MJ, Madduma Hewage SRK, et al. Non-thermal dielectric-barrier discharge plasma damages human keratinocytes by inducing oxidative stress. Int J Mol Med. 2013;37:29–38.

16. Blackert S, Haertel B, Wende K, von Woedtke T, Lindequist U. Influence of non-thermal atmospheric pressure plasma on cellular structures and processes in human keratinocytes (HaCaT). J Dermatol Sci. 2013;70:173–81.

17. Wende K, Landsberg K, Weltmann K-D, von Woedtke T. Distinctive activity of a nonthermal atmospheric-pressure plasma jet on eukaryotic and prokaryotic cells in a cocultivation approach of keratinocytes and microorganisms. IEEE Trans Plasma Sci. 2010;38:2479–85.

18. Hasse S, Duong Tran T, et al. Induction of proliferation of basal epidermal keratinocytes by cold atmospheric-pressure plasma. Clin Exp Dermatol. 2016;41(2):202–9.

19. Arndt S, Landthaler M, Zimmermann JL, et al. Effects of cold atmospheric plasma (CAP) on β-defensins, inflammatory cytokines, and apoptosis-related molecules in keratinocytes in vitro and in vivo. PLoS One. 2015;10:e0120041.

20. Brun P, Pathak S, Castaglioni I, et al. Helium generated cold plasma finely regulates activation of human fibroblast-like primary cells. PLoS One. 2014;9:e104397.

21. Shashurin A, Stepp MA, Hawley TS, et al. Influence of cold plasma atmospheric jet on surface integrin expression of living cells. Plasma Process Polym. 2010;7:294–300.

22. Lopes BB, De Paula Leite Kraft MB, Rehder J, Batista FRX, Puzzi MB. The interactions between non-thermal atmospheric pressure plasma and ex vivo dermal fibroblasts. Proc Eng. 2013;59:92–100.

23. Tipa RS, Kroesen GMW. Plasma-stimulated wound healing. IEEE Trans Plasma Sci. 2011;39:2978–9.

24. Isbary G, Köritzer J, Mitra A, et al. Ex vivo human skin experiments for the evaluation of safety of new cold atmospheric plasma devices. Clin Plasma Med. 2013;1:36–44.

25. Ma R, Feng H, Li F, et al. An evaluation of anti-oxidative protection for cells against atmospheric pressure cold plasma treatment. Appl Phys Lett. 2012;100:3–7.

26. Lademann J, Richter H, Alborova A, et al. Risk assessment of the application of a plasma jet in dermatology. J Biomed Opt. 2009;14:054025.

27. Wende K, Bekeschus S, Schmidt A, et al. Risk assessment of a cold argon plasma jet in respect to its mutagenicity. Mutat Res Genet Toxicol Environ Mutagen. 2016;798–799:48–54.

28. Keidar M. Plasma for cancer treatment. Plasma Sour Sci Technol. 2015;24:033001.

29. Kieft IE, Kurdí M, Stoffels E. Reattachment and apoptosis after plasma-needle treatment of cultured cells. IEEE Trans Plasma Sci. 2006;34:1331–6.

30. Xu D, Liu D, Wang B, et al. In situ OH generation from O2- and H2O2 plays a critical role in plasma-induced cell death. PLoS One. 2015;10:e0128205.

31. Yan D, Talbot A, Nourmohammadi N, et al. Principles of using cold atmospheric plasma stimulated media for cancer treatment. Sci Rep. 2015;17(5):18339.

32. Adachi T, Tanaka H, Nonomura S, et al. Plasma-activated medium induces A549 cell injury via a spiral apoptotic cascade involving the mitochondrial-nuclear network. Free Radic Biol Med. 2015;79:28–44.

33. Utsumi F, Kajiyama H, Nakamura K, et al. Effect of indirect nonequilibrium atmospheric pressure plasma on anti-proliferative activity against chronic chemo-resistant ovarian cancer cells in vitro and in vivo. PLoS One. 2013;8(12):e81576.

34. Sander CS, Hamm F, Elsner P, Thiele JJ. Oxidative stress in malignant melanoma and non-melanoma skin cancer. Br J Dermatol. 2003;148(5):913–22.

35. Ishaq M, Kumar S, Varinli H, et al. Atmospheric gas plasma-induced ROS production activates TNF-ASK1 pathway for the induction of melanoma cancer cell apoptosis. Mol Biol Cell. 2014;25:1523–31.

36. Daeschlein G, Scholz S, Lutze S, et al. Comparison between cold plasma, electrochemotherapy and
combined therapy in a melanoma mouse model. Exp Dermatol. 2013;22:582–6.

37. Welz C, Emmert S, Canis M, et al. Cold atmospheric plasma: a promising complementary therapy for squamous head and neck cancer. PLoS One. 2015;10:e0141827.

38. Maisch T, Shimizu T, Li Y-F, et al. Decolonisation of MRSA, *S. aureus* and *E. coli* by cold-atmospheric plasma using a porcine skin model in vitro. PLoS One. 2012;7:e34610.

39. Klampfl TG, Isbary G, Shimizu T, et al. Cold atmospheric air plasma sterilization against spores and other microorganisms of clinical interest. Appl Environ Microbiol. 2012;78:5077–82.

40. Isbary G, Morfill G, Schmidt HU, et al. A first prospective randomized controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in patients. Br J Dermatol. 2010;163:78–82.

41. Isbary G, Heinlin J, Shimizu T, et al. Successful and safe use of 2 min cold atmospheric argon plasma in chronic wounds: results of a randomized controlled trial. Br J Dermatol. 2012;167:404–10.

42. Brehmer F, Haenssle HA, Daeschlein G, et al. Alleviation of chronic venous leg ulcers with a hand-held dielectric barrier discharge plasma generator (PlasmaDerm® VU-2010): results of a monocentric, two-armed, open, prospective, randomized and controlled trial (NCT01415622). J Eur Acad Dermatol Venereol. 2015;29:148–55.

43. Klebes M, Lademann J, Philipp S, et al. Effects of tissue-tolerable plasma on psoriasis vulgaris treatment compared to conventional local treatment: a pilot study. Clin Plasma Med. 2014;2:22–7.

44. Isbary G, Heinlin J, Shimizu T, et al. Skin decontamination by low-temperature atmospheric-pressure plasma jet and dielectric barrier discharge plasma. J Hosp Infect. 2012;81:177–83.

45. Haertel B, von Woedtke T, Weltmann K-D, Lindequist U. Non-thermal atmospheric-pressure plasma possible application in wound healing. Biomol Ther 2014;22:477–90.

46. Daeschlein G, Scholza S, Ahmed R, et al. Skin decontamination by low-temperature atmospheric-pressure plasma jet and dielectric barrier discharge plasma. J Hosp Infect. 2012;81:177–83.

47. Fluhr JW, Sassning S, Lademann O, et al. In vivo skin treatment with tissue-tolerable plasma influences skin physiology and antioxidant profile in human stratum corneum. Exp Dermatol. 2011;21:130–4.

48. Ishaq M, Bazaka K, Ostrikov K. Pro-apoptotic NOXA is implicated in atmospheric-pressure plasma-induced melanoma cell death. J Phys D Appl Phys. 2015;48:464002.
60. Morfill G, Shimizu T, Steffes B, Schmidt H-U. Nosocomial infections—a new approach towards preventive medicine using plasmas. New J Phys. 2009;11:115019.

61. Li YF, Taylor D, Zimmermann JL, et al. In vivo skin treatment using two portable plasma devices: comparison of a direct and an indirect cold atmospheric plasma treatment. Clin Plasma Med. 2013;1:35–9.

62. Kaushik N, Kumar N, Kim CH, Kaushik NK, Choi EH. Dielectric barrier discharge plasma efficiently delivers an apoptotic response in human monocytic lymphoma. Plasma Process Polym. 2014;11:1175–87.

63. Wang M, Holmes B, Cheng X, Zhu W, Keidar M, Zhang LG. Cold atmospheric plasma for selectively ablating metastatic breast cancer cells. PLoS One. 2013;8:e73741.

64. Iseki S, Nakamura K, Hayashi M, et al. Selective killing of ovarian cancer cells through induction of apoptosis by nonequilibrium atmospheric pressure plasma. Appl Phys Lett. 2012;100:113702.

65. Kim CH, Kwon S, Bahn JH, et al. Effects of atmospheric nonthermal plasma on invasion of colorectal cancer cells. Appl Phys Lett. 2010;96.

66. Joh HM, Choi JY, Kim SJ, Chung TH, Kang T-H. Effect of additive oxygen gas on cellular response of lung cancer cells induced by atmospheric pressure helium plasma jet. Sci Rep. 2014;4:6638.

67. Gweon B, Kim M, Bee Kim D, et al. Differential responses of human liver cancer and normal cells to atmospheric pressure plasma. Appl Phys Lett. 2011;99:063701.

68. Kim JY, Ballato J, Foy P, et al. Apoptosis of lung carcinoma cells induced by a flexible optical fiber-based cold microplasma. Biosens Bioelectron. 2011;28:530–8.

69. Partecke LI, Evert K, Haugk J, et al. Tissue tolerable plasma (TTP) induces apoptosis in pancreatic cancer cells in vitro and in vivo. BMC Cancer. 2012;12:1–10.

70. Guerrero-Preston R, Ogawa T, Uemura M, et al. Cold atmospheric plasma treatment selectively targets head and neck squamous cell carcinoma cells. Int J Mol Med. 2014;34:941–6.

71. Hirst AM, Frame FM, Maitland NJ, Connell DO. Low temperature plasma: a novel focal therapy for localized prostate cancer. Biomed Res Int. 2014;2014:878319.

72. Gibson AR, McCarthy HO, Ali A, O’Connell D, Graham WG. Interactions of a non-thermal atmospheric pressure plasma effluent with PC-3 prostate cancer cells. Plasma Process Polym. 2014;11:1142–9.

73. Weiss M, Gumbel D, Henschmann E-M, et al. Cold atmospheric plasma treatment induces anti-proliferative effects in prostate cancer cells by redox and apoptotic signaling pathways. PLoS One. 2015;10:e0130350.

74. Conway GE, Casey A, Milosavljevic V, Liu Y, Howe O, Cullen PJ, et al. Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide. Br J Cancer. 2016;114(4):435–43.

75. Vandamme M, Robert E, Pesnel S, et al. Antitumor effect of plasma treatment on U87 glioma xenografts: preliminary results. Plasma Process Polym. 2010;7:264–73.

76. Kortiter J, Boxhammer V, Al E. Restoration of sensitivity in chemo-resistant glioma cells by cold atmospheric plasma. PLoS One. 2013;8:1–10.

77. Cheng X, Murphy W, Recek N, et al. Synergistic effect of gold nanoparticles and cold plasma on glioblastoma cancer therapy. J Phys D Appl Phys. 2014;47:335402.

78. Cheng X, Sherman J, Murphy W, Ratovitski E, Canady J, Keidar M. The effect of tuning cold plasma composition on glioblastoma cell viability. PLoS One. 2014;9:1–9.

79. Siu A, Volotskova O, Cheng X, et al. Differential effects of cold atmospheric plasma in the treatment of malignant glioma. PLoS One. 2015;10:e0126313.

80. Walk RM, Snyder J, Srinivasan P, et al. Cold atmospheric plasma for the ablative treatment of neuroblastoma. J Pediatr Surg. 2013;48:67–73.